$-0.92 EPS Expected for Audentes Therapeutics, Inc. (BOLD) on March, 14

On March, 14 is anticipated Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s earnings report, RTT reports. Analysts predict $-0.92 earnings per share, which is $0.10 down or 12.20 % from 2018’s $-0.82 earnings per share. -5.15 % EPS growth is what analysts predict. $-0.97 earnings per share was revealed for previous quarter. BOLD touched $24.72 during the last trading session after $0.81 change.Audentes Therapeutics, Inc. has volume of 249,521 shares. Since February 18, 2018 BOLD has declined 19.28% and is downtrending. The stock underperformed the S&P500 by 19.28%.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States.The company has $1.06 billion market cap. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.Last it reported negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

For more Audentes Therapeutics, Inc. (NASDAQ:BOLD) news released briefly go to: Seekingalpha.com, Nasdaq.com, Globenewswire.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Audentes advancing gene therapy AT132 – Seeking Alpha” released on January 31, 2019, “Aerojet Rocketdyne’s Affordability and Efficiency Drive Achieves Major Milestones – Nasdaq” on February 07, 2019, “Del Frisco’s Restaurant Group Announces Cooperation Agreement with Engaged Capital – GlobeNewswire” with a publish date: February 04, 2019, “Yum! Brands (YUM) Q4 Earnings to Benefit From Refranchising – Nasdaq” and the last “Where Will Apple Stock Be Trading in a Year? – Nasdaq” with publication date: January 24, 2019.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.